The Joe Rogan Experience #2469 – Brigham Buhler

Date: March 18, 2026

Overview

In this deeply insightful episode, Joe Rogan welcomes Brigham Buhler, founder and CEO of Ways2Well, for a wide-ranging conversation on the evolution of healthcare, the regulatory labyrinth around peptides, hormones, and stem cells, and the vision for truly preventative, patient-centered medicine in America. Buhler shares inside perspectives on working with current health officials, exposes the obstacles posed by regulatory dogma and pharmaceutical lobbying, and passionately advocates for a healthcare system that prioritizes innovation and healthspan over profits and status quo thinking.

Key Topics & Timestamps

1. The State of Peptides & Regulatory Change

[03:37–10:00]

• Brigham describes progress with the FDA and reclassification of peptides, emphasizing the role of Secretary Kennedy (who personally uses and understands them) and the new head of the FDA, Marty Makary.
• The Biden administration previously restricted peptides, leaving patients and clinicians without answers; Brigham submitted 17 Freedom of Information Act (FOIA) requests for safety data, none of which received a response.
• Under new leadership, there’s real dialogue: “To go from that environment where you’re being stonewalled...to being able to at least have a seat at the table and a voice is pretty revolutionary.” (Brigham, [02:56])

Notable Quote

“I submitted 17 FOIA requests, 17 to the FDA. They have never once responded to a single FOIA request.”
—Brigham ([02:48])

2. Dogma vs. Science: Hormone Therapy & Testosterone Myths

[06:41–15:15]

• The misconception linking testosterone therapy to prostate cancer is debunked; the fear originates from a tiny, flawed 1930s study.
• No credible modern research supports a link between testosterone/HRT and increased cancer risk—an example of medical dogma overtaking science.
• New FDA leadership is removing black box warnings and working to reverse decades of fear-mongering around hormone therapies for both men and women.

Notable Quotes

“All of the fear with prostate cancer literally comes from a study from the 1930s... There were three patients in the study. One patient dropped out. One patient was chemically castrated.”
—Brigham ([07:12])

“It’s a prime example of the dogma of medicine. Myth becomes reality, right? And misnomer can be adopted, and then it becomes commonplace.”
—Brigham ([14:25])

3. Peptides, Big Pharma, and Regulatory Capture

[15:16–34:00]

• Discussion of how the expense to bring new drugs (~$1–3 billion) protects big pharmaceutical interests—excluding naturally occurring substances like peptides and stem cells from the current system.
• Cash pay model for innovative therapies (peptides, stem cells), not seeking insurance/Medicare coverage, disrupts the "pharma-first" system.
• Lobbying drives regulatory narratives; pharmaceutical giants lobby to extend patents/monopolies, often using taxpayer-funded research.
• Joe & Brigham dissect the Ozempic/GLP-1 peptide weight loss drug controversy and compounded medication issues, revealing hypocrisy in pharma’s approach to overseas ingredient sourcing.

Notable Quotes

“GLP1s are peptides...this is a gigantic market right now.”
—Joe ([19:58])

“When I'm launching a pharmaceutical drug into the market, I'm asking for everybody else to cover the cost of my care... Peptides...is all cash pay. It is outside of the existing ecosystem and structure.”
—Brigham ([18:47])

4. System Failures: Sick Care vs. Proactive Healthspan

[35:16–44:00]

• The “sick care” insurance model treats catastrophic illness but fails at preventing chronic disease.
• Proactive, personalized diagnostics, lifestyle, nutrition, and hormone optimization are stymied by insurance and regulatory inertia.
• Brigham illustrates the difference between “pill mill” cash models versus true concierge, quality-driven, and affordable care—aiming to democratize longevity-focused medicine.

Notable Quotes

“We are absolutely an abysmal failure at preventing chronic disease and driving healthspan.”
—Brigham ([36:41])

“The average American's on four or more prescription drugs. Like, we can't prescribe our way out of this.”
—Joe ([39:14])

5. Pharma Profits, Black Market, and Regulatory Solutions

[44:01–73:15]

• Analysis of GLP-1 (Ozempic) profits—claims of "losing" billions are exaggerated compared to actual earnings.
• The banning of peptides increased black/grey market use; now, 4 out of 5 peptide transactions happen outside legal channels, increasing risk due to lack of oversight.
• Brigham’s regulatory fix: legalize clinician-driven peptide access, eliminate most black market activity, and improve patient safety.

Notable Quotes

“We are living in the Wild West. So my message to Marty, and if you want to fix this, how you fix it is you bring back where we were prior to the mistake of the Biden administration...”
—Brigham ([68:46])

6. Activism at the State Level & the Future of Healthcare Policy

[74:33–83:20]

• States like Texas, Florida, Arizona are leading the way with “right to try” laws for stem cells, peptides, and alternative therapies.
• The hope is that these models will provide the template for federal regulatory change.
• Medical tourism surges in states with progressive health laws.

Notable Quotes

“The states right now are able to move faster and more nimble than the federal government. And the states are building safety nets and checks and balances that will still allow patient accessibility at the state level.”
—Brigham ([76:37])

7. The Genetic Revolution: Personalized Medicine

[93:27–111:30]

• The next healthcare leap: combining gene sequencing, real-world biometrics, and AI to predict and prevent disease.
• Stories from athletes like Gordon Ryan reveal the practical value of gene analysis for health optimization.
• Brigham envisions accessible, affordable genetic insight as the foundation for predictive and precision care for everyone.

Notable Quotes

“Less than one in 1,000 people have ever had their genome sequenced… Genetics is in the infancy of what it's going to be.”
—Brigham ([91:56])

8. MUSE Stem Cells: The (Potential) Holy Grail of Regenerative Medicine

[113:23–137:42]

• Breakthroughs in stem cell therapy: MUSE (Multi-lineage, Stress Enduring) cells are a small, ultra-resilient, pluripotent stem cell subset capable of becoming any cell type and surviving extreme stress.
• Brigham details their discovery, properties, and promise—safe, non-tumorigenic, strong engraftment rates, already used overseas for dramatic patient recoveries.
• Push for a regulatory pathway in the US: “These cells are extremely safe... They hone in at a much stronger rate than traditional MSCs.”

Notable Quotes

“If this is real, this is going to change everything in the regenerative space.”
—Brigham ([113:36])

9. Plasmapheresis & Multi-Modal Protocols for Longevity

[140:48–147:23]

• Plasmapheresis (therapeutic plasma exchange)—known for decades, now being repurposed for longevity and removing toxins like microplastics and endocrine disruptors.
• Example: Chef Philip Franklin Lee corrected low testosterone by clearing microplastics, showing systemic improvement without drugs.

Notable Quotes

“Think of it like an oil change for your body.”
—Brigham ([140:48])

10. Closing Reflections & The Future

[147:27–end]

• Joe and Brigham reflect on the vital need for continued advocacy and openness to innovation.
• Brigham gives credit to Joe for helping move the needle in federal discussions about peptides and patient access.
• Both express optimism about the direction of patient-driven, science-forward, and outcome-based healthcare.

Notable Quotes

“If you weren't here and fighting for peptides and accessibility and you hadn't given me a platform, I don't know if anybody would be helping this administration navigate all this. I really don't.”
—Brigham ([147:41])

Memorable Moments & Quotes

• “My goal is to help you drive healthspan and monetize your health to help you want to be a willing participant, because you feel so good and your mental, cognitive, physical function, your skin, your complexion...”
  —Brigham ([89:43])
• “We should strive to make you superhuman. I mean, that's really my belief. Like, why do you want to have normal hormones when you can have optimal hormones?”
  —Brigham ([101:59])
• “If you're battling a chronic disease and you're going to die, what is the harm in seeing if this can help?”
  —Brigham ([138:07])

Summary Table: Key Regulatory Issues (Timestamps)

| Topic | Timeframe | Key Points | |-----------------------------------|------------------|-------------------------------------------------------------------------------------| | Peptides & Regulatory Status | [03:37–10:00] | Shift from stonewalling to open dialogue; FDA changes; Secretary Kennedy involved. | | Hormone Therapy Myths | [06:41–15:15] | Old dogma vs. new science; Black box warnings to be removed. | | Pharma Lobbying & Drug Pricing | [15:16–34:00] | Lobbying keeps up patents, blocks alternatives; NIH taxpayer-funded research issue. | | Black Market & Access | [44:01–73:15] | 4/5 peptides now black/grey market; need for clinician access to control safety. | | State vs Federal Policy | [74:33–83:20] | States leading on stem cells, right to try laws, model for the federal government. |

Final Takeaways

• Regulatory inertia and pharmaceutical lobbying stall innovation and patient access to safe, effective therapies like peptides, hormones, and stem cells.
• Current momentum—driven by open-minded regulators, state innovation, and data—is moving medicine toward a future where prevention, personalization, and patient autonomy are prioritized.
• The integration of gene sequencing, AI, advanced diagnostics, and newly discovered stem cell therapies marks a paradigm shift from "sick care" to genuine healthcare.
• Building accessible, affordable healthcare “life rafts” outside the insurance system is not only possible but essential for the healthspan of the nation.

(Summary by The Joe Rogan Experience Podcast Summarizer – Episode #2469 featuring Brigham Buhler)